ENDP - Endo International plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
8.33
-0.43 (-4.91%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close8.76
Open8.67
Bid8.33 x 900
Ask8.43 x 1100
Day's Range8.18 - 8.78
52 Week Range5.27 - 18.50
Volume3,523,848
Avg. Volume3,363,191
Market Cap1.869B
Beta (3Y Monthly)1.77
PE Ratio (TTM)N/A
EPS (TTM)-4.61
Earnings DateMay 6, 2019 - May 10, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.27
Trade prices are not sourced from all markets
  • Catalyst (CPRX) Reports Wider Q4 Loss, Focuses on Firdapse
    Zacks4 days ago

    Catalyst (CPRX) Reports Wider Q4 Loss, Focuses on Firdapse

    Catalyst (CPRX) reports wider-than-expected loss in the fourth quarter of 2018.

  • PR Newswire4 days ago

    Endo Announces Publication Of Collagenase Clostridium Histolyticum (CCH) Phase 2 Data In Dermatologic Surgery

    Leading Peer-Reviewed Dermatology Journal Features Phase 2 Data DUBLIN , March 19, 2019 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today announced the publication of Phase 2 data evaluating ...

  • BioDelivery (BDSI) Q4 Earnings In Line, Sales Beat, Stock Up
    Zacks8 days ago

    BioDelivery (BDSI) Q4 Earnings In Line, Sales Beat, Stock Up

    BioDelivery Sciences (BDSI) reports in-line loss in Q4. Sales beat the consensus mark. The company issues encouraging guidance for 2019.

  • PR Newswire9 days ago

    Endo International plc Announces an Upsizing of its Cash Tender Offers and Consent Solicitations

    DUBLIN, March 14, 2019 /PRNewswire/ -- Endo International plc (ENDP) today announced an upsizing of its previously announced cash tender offers (the "Tender Offers") and consent solicitations by Endo Finance LLC ("Endo Finance"), a wholly-owned subsidiary of Endo International plc. Endo Finance amended the Tender Offers to increase (i) the Aggregate Purchase Price (as defined below) from the initial amount of $1.0 billion to $1.5 billion for all of the Notes (as defined below) validly tendered and not validly withdrawn in the Tender Offers and (ii) the Acceptance Sublimit (as defined below) from the initial aggregate amount of $500.0 million to $650.0 million. All other terms of the Tender Offers and the related consent solicitations, as previously announced, remain unchanged.

  • PR Newswire9 days ago

    Endo International plc Announces Pricing of Private Offering Of Senior Secured Notes

    DUBLIN, March 14, 2019 /PRNewswire/ -- Endo International plc (ENDP) ("Endo") today announced that Par Pharmaceutical, Inc. (the "Issuer"), its wholly-owned subsidiary, priced $1.5 billion aggregate principal amount of 7.500% senior secured notes due 2027 at an issue price of $1,000 per $1,000 principal amount in connection with its previously announced private offering, which represents an upsize of $500.0 million over the previously contemplated offering amount. The notes will be senior secured obligations of the Issuer and will be guaranteed by Endo and certain of Endo's subsidiaries and will be secured by first priority liens on the same collateral that secures Endo's obligations under its existing senior secured credit facilities and existing senior secured notes. Endo intends to use the net proceeds from the offering, together with cash on hand, to fund cash tender offers (the "Tender Offers") by Endo Finance LLC, a wholly-owned subsidiary of Endo, to purchase a portion of Endo's outstanding senior unsecured notes and to pay certain related premiums, fees and expenses.

  • Moody's9 days ago

    Endo Finance Co. -- Moody's downgrades Endo's secured debt to Ba3, unsecured notes to Caa1; B2 CFR affirmed

    Moody's Investors Service ("Moody's") downgraded the senior secured ratings of Endo Luxembourg Finance I Company S.à.r.l. Moody's also assigned a Ba3 rating to the proposed secured revolving credit facility and to the proposed secured notes being issued by Par Pharmaceuticals, Inc., a subsidiary of Endo. The notes will have the same upstream and downstream guarantees as Endo's other secured debt.

  • Insys Plunges on Auditor's Concern About Insufficient Funds
    Zacks9 days ago

    Insys Plunges on Auditor's Concern About Insufficient Funds

    Insys Therapeutics' (INSY) shares plunge after its auditor raises concerns related to insufficiency of funds to continue operations.

  • PR Newswire9 days ago

    Endo International plc Announces Debt Refinancing Transactions, Including Cash Tender Offers and Consent Solicitations for up to $1.0 billion Aggregate Purchase Price of its Outstanding Senior Notes

    DUBLIN, March 14, 2019 /PRNewswire/ -- Endo International plc (ENDP) today announced a series of debt refinancing transactions that are intended to help manage the debt maturity profile of it and certain of its subsidiaries (collectively, the "Company" or "Endo").

  • PR Newswire9 days ago

    Endo International plc Announces Proposed Private Offering Of Senior Secured Notes

    DUBLIN, March 14, 2019 /PRNewswire/ -- Endo International plc (ENDP) ("Endo") today announced that Par Pharmaceutical, Inc. (the "Issuer"), its wholly-owned subsidiary, intends to offer senior secured notes, subject to market and customary conditions. The notes will be senior secured obligations of the Issuer and will be guaranteed by Endo and certain of Endo's subsidiaries and will be secured by first priority liens on the same collateral that secures Endo's obligations under its existing senior secured credit facilities and existing senior secured notes. Endo intends to use the net proceeds from the proposed offering, together with cash on hand, to fund cash tender offers (the "Tender Offers") by Endo Finance LLC, a wholly-owned subsidiary of Endo, to purchase a portion of Endo's outstanding senior unsecured notes and to pay certain related premiums, fees and expenses.

  • Is Endo International (ENDP) a Great Stock for Value Investors?
    Zacks11 days ago

    Is Endo International (ENDP) a Great Stock for Value Investors?

    Is Endo International (ENDP) a great pick from the value investor's perspective right now? Read on to know more.

  • Reuters12 days ago

    Opioid litigation concerns weigh on pharmaceutical loan borrowers

    The opioid crisis came to the loan market last week, as the potential fallout from lawsuits weighed on manufacturers of the drugs cited as a root cause of the epidemic. Pharmaceutical company Endo International’s US$3.4bn term loan was quoted at 97.75-98.5 on Monday, unchanged from Friday but down from 99.625-100.125 on March 4, as its stock fell 23% during the same five-day period. The drop followed a Reuters report that fellow drug producer Purdue Pharma, the maker of OxyContin, was exploring bankruptcy to address liabilities stemming from lawsuits tied to the opioid crisis.

  • What’s Expected to Drive Endo’s Growth in Fiscal 2019?
    Market Realist12 days ago

    What’s Expected to Drive Endo’s Growth in Fiscal 2019?

    Comparing Generic Pharma Stocks: Endo versus Mallinckrodt(Continued from Prior Part)Financial performanceIn fiscal 2018, Endo International’s (ENDP) revenue fell 15.04% YoY (year-over-year) to $2.95 billion but beat its guidance of $2.87

  • Comparing Endo’s and Mallinckrodt’s Gross Margin Forecasts
    Market Realist12 days ago

    Comparing Endo’s and Mallinckrodt’s Gross Margin Forecasts

    Comparing Generic Pharma Stocks: Endo versus Mallinckrodt(Continued from Prior Part)Gross margin comparison In its fourth-quarter conference call, Endo International (ENDP) guided for its gross margin contracting YoY (year-over-year) in fiscal 2019

  • How Endo’s and Mallinckrodt’s Expense Control Stacks Up
    Market Realist12 days ago

    How Endo’s and Mallinckrodt’s Expense Control Stacks Up

    Comparing Generic Pharma Stocks: Endo versus Mallinckrodt(Continued from Prior Part)Expense guidance for fiscal 2019 In its fourth-quarter investor presentation, Endo International (ENDP) guided for its fiscal 2019 adjusted operating expenses as a

  • Endo International’s and Mallinckrodt’s EPS Growth Expectations
    Market Realist15 days ago

    Endo International’s and Mallinckrodt’s EPS Growth Expectations

    Comparing Generic Pharma Stocks: Endo versus Mallinckrodt(Continued from Prior Part)Earnings guidance for fiscal 2019 In its fourth-quarter investor presentation, Endo International (ENDP) guided for adjusted diluted EPS and adjusted EBITDA of

  • Comparing Endo’s and Mallinckrodt’s Revenue Forecasts
    Market Realist15 days ago

    Comparing Endo’s and Mallinckrodt’s Revenue Forecasts

    Comparing Generic Pharma Stocks: Endo versus Mallinckrodt(Continued from Prior Part)Revenue guidance for fiscal 2019 In its fourth-quarter investor presentation, Endo International (ENDP) guided for fiscal 2019 revenue of $2.76 billion–$2.96

  • Analysts’ Views on Endo International and Mallinckrodt
    Market Realist15 days ago

    Analysts’ Views on Endo International and Mallinckrodt

    Comparing Generic Pharma Stocks: Endo versus MallinckrodtStock movement On March 5, Endo International (ENDP) closed at $8.72, 6.54% lower than its previous closing price, 65.46% higher than its 52-week low of $5.27, and 52.86% below its 52-week high

  • Endo (ENDP) Soars: Stock Adds 6% in Session
    Zacks15 days ago

    Endo (ENDP) Soars: Stock Adds 6% in Session

    Endo (ENDP) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

  • State Pensions Fought Guns and Tobacco. Why Aren’t They Divesting From Opioids?
    Bloomberg15 days ago

    State Pensions Fought Guns and Tobacco. Why Aren’t They Divesting From Opioids?

    Some of the biggest ones, including New York and California pension funds, hold investments in Endo International, the largest maker of branded opioids after privately held Purdue Pharma LP. “West Virginia is literally and metaphorically ground zero for both the opioid epidemic and litigation,” said Charles Webb, an attorney at Webb Law Centre, which represents towns that brought suits.

  • GlobeNewswire16 days ago

    Report: Exploring Fundamental Drivers Behind Procter & Gamble, Consolidated Edison, Lennar, Endo International plc, Box, and FRONT YARD RESIDENTIAL CORP — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, March 07, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.

  • What's in Store for BioSpecifics (BSTC) This Earnings Season?
    Zacks18 days ago

    What's in Store for BioSpecifics (BSTC) This Earnings Season?

    BioSpecifics (BSTC) is expected to provide updates on Xiaflex and its pipeline candidates in its fourth quarter earnings call.

  • FDA ruling on compounding goes Endo's way
    American City Business Journals18 days ago

    FDA ruling on compounding goes Endo's way

    The federal agency determined said there is no clinical need to compound vasopressin, a decision that benefits Endo.

  • Endo International plc (NASDAQ:ENDP) Insiders Have Been Selling
    Simply Wall St.19 days ago

    Endo International plc (NASDAQ:ENDP) Insiders Have Been Selling

    We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is that there are more than a few examplesRead More...

  • Implied Volatility Surging for Endo (ENDP) Stock Options
    Zacks19 days ago

    Implied Volatility Surging for Endo (ENDP) Stock Options

    Investors need to pay close attention to Endo (ENDP) stock based on the movements in the options market lately.

  • PR Newswire19 days ago

    Endo to Participate at Cowen & Company 39th Annual Healthcare Conference

    DUBLIN , March 4, 2019 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that members of management will participate in a fireside chat at the Cowen & Company 39 th Annual Healthcare ...